Cilomilast (SB-207499)是一种口服有效的选择性磷酸二酯酶4 (PDE4)抑制剂。该化合物具有抗炎与免疫调节活性,适用于哮喘和慢性阻塞性肺疾病（COPD）的相关研究。
|
英文别名 (English Synonym) |
Cilomilast |
|
中文名称 (Chinese Name) |
西洛司特 |
|
靶点 (Target) |
PDE |
|
通路 (Pathway) |
Protease/Metabolic Enzyme |
|
CAS号 (CAS NO.) |
153259-65-5 |
|
分子式 (Formula) |
C20H25NO4 |
|
分子量 (Molecular Weight) |
343.42 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001 Apr,297(1):267-79. PMID: 11259554.[2]Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther. 1998 Nov,287(2):705-11. PMID: 9808700.
